It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The transition from pluripotent to somatic states marks a critical event in mammalian development, but remains largely unresolved. Here we report the identification of SS18 as a regulator for pluripotent to somatic transition or PST by CRISPR-based whole genome screens. Mechanistically, SS18 forms microscopic condensates in nuclei through a C-terminal intrinsically disordered region (IDR) rich in tyrosine, which, once mutated, no longer form condensates nor rescue SS18−/− defect in PST. Yet, the IDR alone is not sufficient to rescue the defect even though it can form condensates indistinguishable from the wild type protein. We further show that its N-terminal 70aa is required for PST by interacting with the Brg/Brahma-associated factor (BAF) complex, and remains functional even swapped onto unrelated IDRs or even an artificial 24 tyrosine polypeptide. Finally, we show that SS18 mediates BAF assembly through phase separation to regulate PST. These studies suggest that SS18 plays a role in the pluripotent to somatic interface and undergoes liquid-liquid phase separation through a unique tyrosine-based mechanism.
Emerging evidence suggests that exit from pluripotency is a regulated, rather than passive process. Here the authors identify a requirement for SS18-mediated Brg/Brahma-associated factors (BAF) chromatin remodeling complex assembly during exit from pluripotency, and that SS18 promotes BAF assembly through liquidliquid phase separation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, CAS Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou, China (GRID:grid.428926.3) (ISNI:0000 0004 1798 2725); Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, China (GRID:grid.428926.3) (ISNI:0000 0004 1798 2725); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
2 Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, CAS Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou, China (GRID:grid.428926.3) (ISNI:0000 0004 1798 2725)
3 Lanzhou University, School of Physical Science and Technology, Lanzhou, China (GRID:grid.32566.34) (ISNI:0000 0000 8571 0482)
4 Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, CAS Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou, China (GRID:grid.428926.3) (ISNI:0000 0004 1798 2725); Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, China (GRID:grid.428926.3) (ISNI:0000 0004 1798 2725)
5 Guangzhou Medical University, GMU-GIBH Joint School of Life Sciences, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)
6 University of Science and Technology of China, School of Life Sciences, Hefei, China (GRID:grid.59053.3a) (ISNI:0000000121679639)
7 Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, CAS Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou, China (GRID:grid.428926.3) (ISNI:0000 0004 1798 2725); Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, China (GRID:grid.428926.3) (ISNI:0000 0004 1798 2725); Guangzhou Medical University, GMU-GIBH Joint School of Life Sciences, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)
8 Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, CAS Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou, China (GRID:grid.428926.3) (ISNI:0000 0004 1798 2725); Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, China (GRID:grid.428926.3) (ISNI:0000 0004 1798 2725); Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China (GRID:grid.508040.9)
9 Westlake University, Laboratory of Cell Fate Control, School of Life Sciences, Hangzhou, China (GRID:grid.494629.4) (ISNI:0000 0004 8008 9315)